These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 24423253)

  • 21. Inhibition of in vitro transcription by a triplex-forming oligonucleotide targeted to human c-myc P2 promoter.
    Kim HG; Miller DM
    Biochemistry; 1995 Jun; 34(25):8165-71. PubMed ID: 7794930
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective inhibition of the human tie-1 promoter with triplex-forming oligonucleotides targeted to Ets binding sites.
    Hewett PW; Daft EL; Laughton CA; Ahmad S; Ahmed A; Murray JC
    Mol Med; 2006; 12(1-3):8-16. PubMed ID: 16838069
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Triple-helix formation induces recombination in mammalian cells via a nucleotide excision repair-dependent pathway.
    Faruqi AF; Datta HJ; Carroll D; Seidman MM; Glazer PM
    Mol Cell Biol; 2000 Feb; 20(3):990-1000. PubMed ID: 10629056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improved bioactivity of G-rich triplex-forming oligonucleotides containing modified guanine bases.
    Rogers FA; Lloyd JA; Tiwari MK
    Artif DNA PNA XNA; 2014; 5(1):e27792. PubMed ID: 25483840
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cross-linking to an interrupted polypurine sequence with a platinum-modified triplex-forming oligonucleotide.
    Campbell MA; Miller PS
    J Biol Inorg Chem; 2009 Aug; 14(6):873-81. PubMed ID: 19350290
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DNA binding and antigene activity of a daunomycin-conjugated triplex-forming oligonucleotide targeting the P2 promoter of the human c-myc gene.
    Carbone GM; McGuffie E; Napoli S; Flanagan CE; Dembech C; Negri U; Arcamone F; Capobianco ML; Catapano CV
    Nucleic Acids Res; 2004; 32(8):2396-410. PubMed ID: 15121897
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Triple helix formation by (G,A)-containing oligonucleotides: asymmetric sequence effect.
    Arimondo PB; Barcelo F; Sun JS; Maurizot JC; Garestier T; Hélène C
    Biochemistry; 1998 Nov; 37(47):16627-35. PubMed ID: 9843430
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of polyethylenimine-adenovirus complexes to examine triplex formation in intact cells.
    Hoque AT; Sedelnikova OA; Luu AN; Swaim WD; Panyutin IG; Baum BJ
    Antisense Nucleic Acid Drug Dev; 2000 Aug; 10(4):229-41. PubMed ID: 10984117
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting bcl-2 by triplex-forming oligonucleotide--a promising carrier for gene-radiotherapy.
    Shen C; Rattat D; Buck A; Mehrke G; Polat B; Ribbert H; Schirrmeister H; Mahren B; Matuschek C; Reske SN
    Cancer Biother Radiopharm; 2003 Feb; 18(1):17-26. PubMed ID: 12667305
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Triplex formation at the rat neu oncogene promoter.
    Gee JE; Yen RL; Hung MC; Hogan ME
    Gene; 1994 Nov; 149(1):109-14. PubMed ID: 7958974
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transcription inhibition induced by modified triple helix-forming oligonucleotides: a quantitative assay for evaluation in cells.
    Faria M; Wood CD; White MR; Hélène C; Giovannangeli C
    J Mol Biol; 2001 Feb; 306(1):15-24. PubMed ID: 11178890
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gene targeting via triple-helix formation.
    Casey BP; Glazer PM
    Prog Nucleic Acid Res Mol Biol; 2001; 67():163-92. PubMed ID: 11525382
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Specificity of DNA triple helix formation analyzed by a FRET assay.
    Reither S; Jeltsch A
    BMC Biochem; 2002 Sep; 3():27. PubMed ID: 12323077
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Triplex targeting of human PDGF-B (c-sis, proto-oncogene) promoter specifically inhibits factors binding and PDGF-B transcription.
    Liu J; Xu R; Jin Y; Wang D
    Nucleic Acids Res; 2001 Feb; 29(3):783-91. PubMed ID: 11160902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intercalator conjugates of pyrimidine locked nucleic acid-modified triplex-forming oligonucleotides: improving DNA binding properties and reaching cellular activities.
    Brunet E; Corgnali M; Perrouault L; Roig V; Asseline U; Sørensen MD; Babu BR; Wengel J; Giovannangeli C
    Nucleic Acids Res; 2005; 33(13):4223-34. PubMed ID: 16049028
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fluorescent intercalator displacement replacement (FIDR) assay: determination of relative thermodynamic and kinetic parameters in triplex formation--a case study using triplex-forming LNAs.
    Sau SP; Kumar P; Sharma PK; Hrdlicka PJ
    Nucleic Acids Res; 2012 Nov; 40(21):e162. PubMed ID: 22855561
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel triplex-forming oligonucleotide targeted to human cyclin D1 (bcl-1, proto-oncogene) promoter inhibits transcription in HeLa cells.
    Kim HG; Miller DM
    Biochemistry; 1998 Feb; 37(8):2666-72. PubMed ID: 9485417
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Formation and thermodynamic stability of intermolecular (R*R*Y) DNA triplex in GAA/TTC repeats associated with Freidreich's ataxia.
    Jain A; Rajeswari MR; Ahmed F
    J Biomol Struct Dyn; 2002 Feb; 19(4):691-9. PubMed ID: 11843630
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A new approach to overcome potassium-mediated inhibition of triplex formation.
    Svinarchuk F; Cherny D; Debin A; Delain E; Malvy C
    Nucleic Acids Res; 1996 Oct; 24(19):3858-65. PubMed ID: 8871568
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Suppression of insulin-like growth factor type I receptor by a triple-helix strategy inhibits IGF-I transcription and tumorigenic potential of rat C6 glioblastoma cells.
    Rininsland F; Johnson TR; Chernicky CL; Schulze E; Burfeind P; Ilan J
    Proc Natl Acad Sci U S A; 1997 May; 94(11):5854-9. PubMed ID: 9159164
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.